Cardiac fibroblast inflammasome and atrial myopathy
Active Project Grant Awarded Last action
- Award ID
- R01HL163277
- Recipient
-
Baylor College Of Medicine UEI FXKMA43NTV21
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,988,519
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 93% complete
- Originally
- Funding
-
- $8,273,792.00 Federal
- $714,727.00 Non-federal
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
Description
- Abstract
- Atrial fibrillation (AF) is the most frequent arrhythmia. Atrial myopathy is a key determinant of the development of AF. The molecular mechanisms underlying the evolution of AF-promoting atrial myopathy are complex and poorly understood. Innate inflammatory signaling including the 'NLR family pyrin domain containing 3' (NLRP3) inflammasome pathway can modulate cardiac function and atrial arrhythmogenesis. Our preliminary study revealed that NLRP3 inflammasome activity is enhanced in atrial cardiac fibroblasts (CFS) of persistent AF patients compared with sinus rhythm controls. The CF-specific activation of NLRP3 in mice promotes the development of atrial fibrosis, enlarged left atrium, reduced atrial contractility, abnormal impulse conduction, sinus node dysfunction, and increased AF susceptibility, phenocopying atrial myopathy associated with AF development. In this proposal, we will test the hypothesis that activation of CF inflammasomes enhances atrial arrhythmogenesis by promoting atrial myopathy. Additionally, the therapeutic potential of enhancing the resolution of inflammation to combat atrial myopathy and atrial arrhythmogenesis deserves evaluation. In this proposal, we will also evaluate whether an inducer of inflammation resolution can prevent the inflammasome- induced atrial myopathy, thereby reducing atrial arrhythmogenesis. This proposal addresses several understudied areas in AF pathogenesis. The outcome of this study will provide novel insights into the development of atrial myopathy and sinus node dysfunction, as well as provide rationale for using the pro- resolution molecule in AF prevention.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $69,972 | $0 | |
| Amendment | $69,972 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $55,978 | $0 | |
| Amendment | $55,978 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $629,755 | $0 | |
| Amendment | $699,727 | $0 | |
| Amendment | $699,727 | $0 | |
| Amendment | $699,727 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $714,727 | $0 | |
| Amendment | $714,727 | $714,727 | |
| Original award | $714,727 | $0 |
Show all 20
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Universitätsklinikum Essen (Anstalt DES Öffentlichen Rechts) | $296,864 |
Quick answers
Who received award R01HL163277?
R01HL163277 was awarded to Baylor College Of Medicine by National Heart Lung and Blood Institute (National Institutes of Health) on March 25, 2022.
How much is award R01HL163277 worth?
$8,988,519 has been obligated on R01HL163277: $8,273,792 in federal funding and $714,727 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award